Piper Jaffray is out with its report today on Valeant Pharmaceuticals VRX, reiterating Overweight.
In a note to clients, Piper Jaffray writes, "With strong cash flows, plus additional M&A activity, we believe VRX is attractive. Our $65 PT is based on our 2014 EPS of $4.71 (down from $4.76), times a P/E of 16x, discounted by 1.5 years (down from 1.75 years) at 10%."
At the time of posting, shares of VRX were trading pre-market at $55.15, up 0.27% from Friday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in